| 0 (0%) | 09-27 09:32 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 9.81 | 1-year : | 10.71 |
| Resists | First : | 8.4 | Second : | 9.17 |
| Pivot price | 7.96  |
|||
| Supports | First : | 7.15 | Second : | 5.95 |
| MAs | MA(5) : | 7.66 |
MA(20) : | 8.17 |
| MA(100) : | 7.31 |
MA(250) : | 7.44 |
|
| MACD | MACD : | -0.2 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 34.1 |
D(3) : | 24.8 |
| RSI | RSI(14): 48.8 |
|||
| 52-week | High : | 13.36 | Low : | 4.09 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ ENTA ] has closed above bottom band by 47.0%. Bollinger Bands are 24.8% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 8.03 - 8.07 | 8.07 - 8.1 |
| Low: | 7.39 - 7.43 | 7.43 - 7.47 |
| Close: | 7.83 - 7.9 | 7.9 - 7.96 |
Sat, 27 Sep 2025
Enanta to post mid-stage trial data for RSV drug (ENTA:NASDAQ) - Seeking Alpha
Fri, 26 Sep 2025
Clinical Trial Results Coming: Enanta's Novel RSV Treatment for High-Risk Adults Under Spotlight - Stock Titan
Tue, 23 Sep 2025
Two-state solution for Israel-Gaza conflict, as Trump ready to address UN General Assembly - BBC
Sun, 21 Sep 2025
ENTA.spinalTap - The North State Journal
Tue, 16 Sep 2025
Evercore Maintains Enanta Pharmaceuticals(ENTA.US) With Buy Rating, Cuts Target Price to $12 - 富途牛牛
Mon, 15 Sep 2025
Evercore ISI Group Lowers Price Target for Enanta Pharma (ENTA) | ENTA Stock News - GuruFocus
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
|
|
|
Sector:
|
|
|
Industry:
|
|
| Shares Out | 21 (M) |
| Shares Float | 14 (M) |
| Held by Insiders | 6.6 (%) |
| Held by Institutions | 86.5 (%) |
| Shares Short | 2,830 (K) |
| Shares Short P.Month | 2,730 (K) |
| EPS | -4.33 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 3.71 |
| Profit Margin | -142 % |
| Operating Margin | -103.2 % |
| Return on Assets (ttm) | -17.3 % |
| Return on Equity (ttm) | -80.7 % |
| Qtrly Rev. Growth | 1.8 % |
| Gross Profit (p.s.) | 3.03 |
| Sales Per Share | 3.03 |
| EBITDA (p.s.) | -4.36 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -23 (M) |
| Levered Free Cash Flow | -31 (M) |
| PE Ratio | -1.83 |
| PEG Ratio | 0 |
| Price to Book value | 2.12 |
| Price to Sales | 2.6 |
| Price to Cash Flow | -7.29 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|